Targeting C5ar1 Shows Early Promise as New Therapy for Gaucher Disease Blocking a molecule that drives inflammation and organ damage in Gaucher disease and other lysosomal storage diseases (lsds) shows potential as less risky, lower-cost alternative to current therapies, according to findings recently published in Nature.
Read Featured Research| Research and Training Details | |
|---|---|
| Faculty | 30 |
| Joint Appointment Faculty | 5 |
| Research Fellows and Post Docs | 9 |
| Research Graduate Students | 17 |
| Total Annual Grant Award Dollars | $3,138,499 |
| Total Annual Industry Award Dollars | $696,070 |
| Clinical Activities and Training | |
|---|---|
| Clinical Fellows | 5 |
| Inpatient Encounters | 723 |
| Outpatient Encounters | 5,645 |